TICKERNERD
Menu
NXLNXLHealthcare · Medical Devices

NXL Stock Forecast: Nexalin Technology, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$1.60

The 1 Wall Street analysts covering Nexalin Technology, Inc. hold a median 12-month price target of $15 — +837.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 34 of 100 as at 31 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.7M
Ticker Nerd rank
34/ 100
Median analyst target
$15
Analysts covering
1
Revenue$12K−82.8% y/y
Operating income−$2.2M
Net income−$2.2M
Free cash flow−$1.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

NXL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Nexalin Technology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
34/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
98
Growth
96
Accruals
68
Revisions
34
Issuance
33
Momentum
31
Quality
15
Volatility
8
Value
8

Size (98): Smaller than most of the companies we track.

Value (8): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

NXL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NXL, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $15Median $15High $15

The green dot is the last close — the median target sits +837.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 Mar 2025Maxim GroupUpgradeBuy$5.00
24 Mar 2025Maxim GroupUpgradeBuy—
5 Dec 2024Maxim GroupDowngradeHold—
9 Oct 2024Maxim GroupInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

NXL appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Estimates

NXL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Nexalin Technology, Inc. (NXL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.2×

Cheaper than 88% of US stocks

Price / sales
7.7×

Cheaper than 16% of US stocks

Price / book
0.8×

Cheaper than 76% of US stocks

EV / EBITDA
−0.0×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
−82.8%

Higher than 3% of US stocks

Earnings growth (YoY)
−82.8%

Higher than 5% of US stocks

Gross margin
73.2%

Higher than 85% of US stocks

Operating margin
−18479.7%

Higher than 1% of US stocks

Net margin
79.7%

Higher than 98% of US stocks

Returns & dividend
Return on equity
−240.3%

Higher than 6% of US stocks

Return on assets
−119.2%

Higher than 2% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Nexalin Technology, Inc. (NXL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Nexalin Technology, Inc. has a market value of $1.7M and an enterprise value of $170K.

  • Revenue in the twelve months to 30 June 2026: $217K. The latest quarter shrank 82.8% year on year.

  • Net income over the same four quarters: −$9.0M, a −4139.4% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$6.3M.

  • Shares outstanding: 22.0M.

  • Trailing P/E: −3.2×; forward P/E: −0.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Nexalin Technology, Inc. employs 8 people — $27K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 31 Oct 2026

Data provided by Twelve Data

Peers

NXL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
NXLNexalin Technology, Inc.$1.7M34
GCTKGlucoTrack, Inc.$1.6M—
ADGMAdagio Medical Holdings, Inc.$2.3M29
IVFINVO Fertility, Inc.$2.3M34
BJDXBluejay Diagnostics, Inc.$2.5M20
POASPhaos Technology Holdings (Cayman) Ltd.$2.7M2
VJETFlyte Aviation, Inc.$1.2M26

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Nexalin Technology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NXL news & analysis

Nexalin Technology Announces Fourth Peer-Reviewed Publication in Alzheimer's Disease: 15 mA DIFS™ Significantly Improves Sleep Quality in Patients with Mild Alzheimer's Disease

GlobeNewsWire · 27 Oct 2026positive

Nexalin announced a fourth peer-reviewed publication on its 15 mA DIFS™ technology in Alzheimer's disease. The TRANSFORM-AD analysis, published in the Journal of Alzheimer's Disease, reported significantly improved sleep quality versus sham in patients with mild Alzheimer's disease (p < 0.001) and no serious adverse events.

Why it matters — The publication adds peer-reviewed clinical findings about Nexalin's DIFS™ technology in mild Alzheimer's disease, including sleep quality outcomes.

Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing

GlobeNewsWire · 8 Oct 2026positive

Nexalin Technology said it regained compliance with Nasdaq’s minimum bid price requirement, and a Nasdaq Hearings Panel granted its request for continued listing. The company said it remains focused on transitioning toward commercial revenue generation and advancing its U.S. clinical programs.

Why it matters — The update addresses NXL’s Nasdaq listing status and outlines the company’s stated commercial and clinical priorities.

Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in its Transition Toward Commercial Revenue Generation

GlobeNewsWire · 1 Oct 2026positive

Nexalin Technology has signed a definitive exclusive distribution and local manufacturing agreement for Brazil and South America, covering seven countries and more than 300 million people. The agreement includes an initial 100-device commercialization program for its ANVISA-approved Nexalin Sync device, with a structured pricing framework and a mechanism for larger strategic transactions with government and private-sector customers.

Why it matters — This marks a significant step in Nexalin's transition toward commercial revenue generation, expanding access to its ANVISA-approved device across South America while establishing a foundation for larger strategic deals.

Nexalin Technology Taps Neuromodulation Commercial Executive Robert DiTota to Advise on its Global Commercialization Strategy

GlobeNewsWire · 29 Sept 2026positive

Nexalin Technology announced the appointment of Robert DiTota as Senior Strategic Advisor, Global Commercialization, effective September 15, 2026. DiTota, who spent over two decades in neuromodulation at Abbott and Medtronic, will help Nexalin develop distribution relationships, go-to-market plans, and commercial infrastructure to convert its existing regulatory approvals in China, Brazil, Oman, and Israel into commercial sales.

Why it matters — The appointment signals Nexalin's move from clinical development toward commercialization of its DIFS platform, bringing experienced neuromodulation leadership to help convert its regulatory approvals into actual sales across the US, Europe, and South America.

Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer's Patients; ADAS-Cog Subscale Analysis to Guide Design of Planned U.S. Alzheimer's Pilot Study

GlobeNewsWire · 3 Sept 2026positive

Nexalin Technology announced a new secondary analysis of data from its previously published randomized, sham-controlled clinical trial, revealing previously unreported improvements in memory, comprehension, and language function in Alzheimer's patients. The company said the ADAS-Cog subscale analysis will help guide the design of its planned U.S. Alzheimer's pilot study.

Why it matters — For NXL watchers, this analysis highlights new, previously unreported cognitive benefits from the company's trial data and directly informs the design of its upcoming U.S. Alzheimer's pilot study.

FAQ

Frequently asked questions about NXL stock

What is the NXL stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Nexalin Technology, Inc. have a median 12-month price target of $15, with estimates ranging from $15 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NXL stock a buy right now?

Of the 1 analysts covering Nexalin Technology, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nexalin Technology, Inc. 34 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NXL?

As at 31 Oct 2026, Nexalin Technology, Inc. ranks 34 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

Will NXL stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +837.5% from the last close, and Ticker Nerd's factor model ranks Nexalin Technology, Inc. 34 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NXL stock forecast for 2030?

No analyst covering Nexalin Technology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NXL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $15 over the next 12 months.

What does Nexalin Technology, Inc. do?

Nexalin Technology, Inc. Common Stock represents an equity interest in Nexalin Technology, Inc., a medical device company focused on neurostimulation products for mental health and related neurological conditions.

What is the latest news on NXL?

The most recent item we track (GlobeNewsWire, 27 Oct 2026): "Nexalin Technology Announces Fourth Peer-Reviewed Publication in Alzheimer's Disease: 15 mA DIFS™ Significantly Improves Sleep Quality in Patients with Mild Alzheimer's Disease". Nexalin announced a fourth peer-reviewed publication on its 15 mA DIFS™ technology in Alzheimer's disease. The TRANSFORM-AD analysis, published in the Journal of Alzheimer's Disease, reported significantly improved sleep quality versus sham in patients with mild Alzheimer's disease (p < 0.001) and no serious adverse events.

Company

About Nexalin Technology, Inc.

Nexalin Technology, Inc. Common Stock represents an equity interest in Nexalin Technology, Inc., a medical device company focused on neurostimulation products for mental health and related neurological conditions. The company develops noninvasive bioelectronic systems designed to deliver targeted stimulation through headset-based and forehead-mounted devices, with applications in areas such as anxiety, insomnia, depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, chronic pain, and other brain-health conditions. Nexalin Technology serves clinicians and patients through products intended for use in medical settings and, in some cases, at home under professional guidance. Its product portfolio is centered on neuromodulation therapies that aim to provide drug-free treatment options within the healthcare and medical technology markets. The stock is used by investors to track ownership in a specialized healthcare company operating at the intersection of medical devices, digital health, and neurotechnology.

CEO Mr. Mark White · 8 employees · United States · https://www.nexalin.com